The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and
From streamlining clinical trials to evaluating drug repurposing possibilities for new patient populations and addressing critical supply chain challenges, 2024 will be the year artificial
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
